Holen Sie sich die Stockscreener-App
40.99
0.68%
-0.28
Handel nachbörslich:
40.99
Schlusskurs vom Vortag:
$41.27
Offen:
$40.79
24-Stunden-Volumen:
1.09M
Relative Volume:
0.98
Marktkapitalisierung:
$9.11B
Einnahmen:
$1.94B
Nettoeinkommen (Verlust:
$72.70M
KGV:
28.27
EPS:
1.45
Netto-Cashflow:
$405.21M
1W Leistung:
-6.95%
1M Leistung:
-4.67%
6M Leistung:
-10.29%
1J Leistung:
+1.01%
1-Tages-Spanne:
$40.73
$41.20
1-Wochen-Bereich:
$40.73
$43.99
52-Wochen-Spanne:
$39.03
$47.44
Qiagen Nv Stock (QGEN) Company Profile
Firmenname
Qiagen Nv
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie QGEN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| QGEN | 40.99 | 9.11B | 1.94B | 72.70M | 405.21M | 1.45 |
| TMO | 501.29 | 192.46B | 42.37B | 6.14B | 7.78B | 15.26 |
| DHR | 230.06 | 166.23B | 23.74B | 3.89B | 4.98B | 7.93 |
| A | 126.92 | 36.47B | 6.50B | 1.41B | 1.42B | 3.82 |
| IQV | 191.04 | 34.67B | 15.32B | 1.41B | 1.96B | 5.95 |
| IDXX | 419.83 | 34.38B | 3.84B | 866.24M | 792.60M | 9.80 |
Qiagen Nv Stock (QGEN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-12-19 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-12-13 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-12-07 | Hochstufung | Goldman | Neutral → Buy |
| 2023-09-12 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-05-23 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-10-18 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-01-18 | Hochstufung | DZ Bank | Hold → Buy |
| 2021-10-15 | Fortgesetzt | Cowen | Market Perform |
| 2021-10-14 | Eingeleitet | Redburn | Buy |
| 2021-07-14 | Herabstufung | Kepler | Buy → Hold |
| 2021-06-03 | Eingeleitet | Goldman | Neutral |
| 2020-10-06 | Fortgesetzt | BofA Securities | Buy |
| 2020-09-28 | Hochstufung | Kepler | Hold → Buy |
| 2020-08-24 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-08-20 | Fortgesetzt | JP Morgan | Overweight |
| 2020-08-17 | Hochstufung | Berenberg | Hold → Buy |
| 2020-08-14 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2020-08-14 | Hochstufung | Exane BNP Paribas | Neutral → Outperform |
| 2020-03-04 | Herabstufung | Berenberg | Buy → Hold |
| 2020-01-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-01-07 | Eingeleitet | Citigroup | Neutral |
| 2019-12-26 | Fortgesetzt | BofA/Merrill | Underperform |
| 2019-11-15 | Eingeleitet | Stifel | Hold |
| 2019-11-14 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-11-14 | Hochstufung | JP Morgan | Underweight → Overweight |
| 2019-11-14 | Hochstufung | Kepler | Reduce → Hold |
| 2019-10-17 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2019-10-09 | Herabstufung | Kepler | Hold → Reduce |
| 2019-10-08 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2019-10-08 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2019-10-08 | Herabstufung | JP Morgan | Neutral → Underweight |
Alle ansehen
Qiagen Nv Aktie (QGEN) Neueste Nachrichten
Natixis Advisors LLC Has $35.41 Million Stock Holdings in Qiagen (NYSE:QGEN) - MarketBeat
180,729 Shares in Qiagen (NYSE:QGEN) Purchased by Impax Asset Management Group plc - MarketBeat
QGEN Collaborates With McGill University Centre: Stock to Gain? - Yahoo Finance Australia
Victory Capital Management Inc. Has $117.33 Million Stock Position in Qiagen (NYSE:QGEN) - MarketBeat
What is William Blair's Estimate for Qiagen FY2024 Earnings? - MarketBeat
Crossmark Global Holdings Inc. Sells 12,133 Shares of Qiagen (NYSE:QGEN) - MarketBeat
Pharmahungary Group participates in ambitious EU EVEREST Project - European Biotechnology News
QIAGEN collaborates with McGill University to advance microbiome research - GlobeNewswire
QIAGEN Partners with McGill to Target $1.8B Microbiome Market in Major Research Deal | QGEN Stock News - StockTitan
Don't Overlook Qiagen (QGEN) International Revenue Trends While Assessing the Stock - Yahoo Finance
QIAGEN NV : UBS reiterates its Neutral rating - Marketscreener.com
Earnings call: QIAGEN tops Q3 expectations, raises 2024 EPS outlook - Investing.com India
Earnings call: QIAGEN tops Q3 expectations, raises 2024 EPS outlook By Investing.com - Investing.com Australia
Qiagen Non-GAAP EPS of $0.46 beats by $0.02, revenue of $459M beats by $2.09M - MSN
Wellington Management Group LLP's Strategic Acquisition of Qiage - GuruFocus.com
Why Qiagen (QGEN) is a Top Value Stock for the Long-Term - Yahoo Finance
Qiagen NV (QGEN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Advancements - GuruFocus.com
Qiagen Reports Strong Q3 2024 Growth - TipRanks
QIAGEN Stock Flat Post Q3 Earnings & Revenue Beat, 2024 EPS View Up - Barchart
Is There An Opportunity With Qiagen N.V.'s (NYSE:QGEN) 31% Undervaluation? - Yahoo Finance
QIAGEN NV : Deutsche Bank reaffirms its Buy rating - Marketscreener.com
Qiagen Q3 24 Earnings Conference Call At 9:30 AM ET - Nasdaq
QIAGEN : Markets hailed the Q3 beat + the profitability upgrade - Marketscreener.com
QIAGEN NV : Receives a Buy rating from Berenberg - Marketscreener.com
Qiagen (NYSE:QGEN) Shares Sold by Van ECK Associates Corp - MarketBeat
Qiagen N : QIAGEN delivers solid Q3 2024 growth ahead of outlook, increases full year 2024 adjusted EPS outlook - Marketscreener.com
QIAGEN NV : UBS reaffirms its Neutral rating - Marketscreener.com
Qiagen N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Compared to Estimates, Qiagen (QGEN) Q3 Earnings: A Look at Key Metrics - Yahoo Finance
Qiagen (QGEN) Q3 Earnings and Revenues Top Estimates - Yahoo Finance
Diagnostics firm Qiagen reports rise in third-quarter revenue - Reuters
QIAGEN delivers solid Q3 2024 growth ahead of outlook, increases full-year 2024 adjusted EPS outlook - The Manila Times
QIAGEN Q3 Earnings Surge: Sales Hit $502M, Boosts 2024 EPS Outlook | QGEN Stock News - StockTitan
Qiagen NV (QGEN) Q3 2024: Everything You Need to Know Ahead of E - GuruFocus.com
FDA clears fourth Qiagen test in 2024 - BioWorld Online
Qiagen NV (QGEN) Q3 2024 Earnings Report Preview: What to Expect - GuruFocus.com
QGEN Stock Set to Gain From FDA's Clearance of QIAstat-Dx Mini Panel - Yahoo Finance
Qiagen (QGEN) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates - Yahoo Finance
QIAGEN receives FDA clearance of QIAstat-Dx meningitis/encephalitis panel to support emergency diagnostics - GlobeNewswire
Qiagen Receives FDA Clearance Of Qiastat-Dx Meningitis/Encephalitis Panel To Support Emergency Diagnostics - XM
Forsta AP Fonden Sells 18,586 Shares of Qiagen (NYSE:QGEN) - MarketBeat
Qiagen (QGEN) Set to Announce Earnings on Wednesday - MarketBeat
Raymond James & Associates Trims Position in Qiagen (NYSE:QGEN) - MarketBeat
Global Exosome Market to Surge at a Tremendous CAGR of ~20% by 2030 | DelveInsight - GlobeNewswire Inc.
QIAGEN receives FDA clearance for QIAstat-Dx mini panel to improve precision in outpatient respiratory treatment - GlobeNewswire
Qiagen Receives FDA Clearance For Qiastat-Dx Mini Panel - XM
Is QIAGEN (QGEN) a Good Investment Now? Key Factors to Note - MSN
Insiders At Qiagen Sold US$7.0m In Stock, Alluding To Potential Weakness - Simply Wall St
Qiagen (NYSE:QGEN) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Finanzdaten der Qiagen Nv-Aktie (QGEN)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.04%
3.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):